BACKGROUND AND AIMS: The aim of this study was to compare blood glucose and plasma insulin profiles after bolus insulin infusion by a patch pump (PP) versus a conventional pump (CP), directly after placement and after Day 3 of use. PATIENTS AND METHODS: Twenty patients with type 1 diabetes came in for two blocks of visits: one block of two visits while wearing the OmniPod® (Insulet Corp., Bedford, MA) insulin pump (PP) and one block of two visits while wearing the Medtronic Diabetes (Northridge, CA) Paradigm® pump (CP). Patients administered an identical mealtime insulin bolus of at least 6 IU. RESULTS:For PP, maximum glucose levels were 28.7% lower on Day 3 (P=0.020), when maximum insulin levels were 30.3% higher (P=0.002). For CP, maximum glucose levels were 26.5% lower on Day 3 (P=0.015), when maximum insulin levels were 46.4% higher (P=0.003). Glucose levels (mean [interquartile range]) were significantly lower on Day 3 for PP (168.2 [145.8] mg/dL vs. 139.4 [77.8] mg/dL; P=0.013), but not significantly so for CP (159.0 [66.1] mg/dL vs. 139.5 [57.9] mg/dL; P=0.084). Mean insulin levels were significantly higher on Day 3 for CP (195 [120] pmol/L vs. 230 [90] pmol/L; P=0.01), but not significantly so for PP (178 [106] pmol/L vs. 194 [120] pmol/L; P=0.099). There were no significant differences between the two catheter lengths. CONCLUSIONS:Postprandial glycemic excursions were lower on Day 3 of catheter wear time, but there were no differences between PPs and CPs. These findings support the proposal that catheter wear time plays an important role in insulin absorption.
RCT Entities:
BACKGROUND AND AIMS: The aim of this study was to compare blood glucose and plasma insulin profiles after bolus insulin infusion by a patch pump (PP) versus a conventional pump (CP), directly after placement and after Day 3 of use. PATIENTS AND METHODS: Twenty patients with type 1 diabetes came in for two blocks of visits: one block of two visits while wearing the OmniPod® (Insulet Corp., Bedford, MA) insulin pump (PP) and one block of two visits while wearing the Medtronic Diabetes (Northridge, CA) Paradigm® pump (CP). Patients administered an identical mealtime insulin bolus of at least 6 IU. RESULTS: For PP, maximum glucose levels were 28.7% lower on Day 3 (P=0.020), when maximum insulin levels were 30.3% higher (P=0.002). For CP, maximum glucose levels were 26.5% lower on Day 3 (P=0.015), when maximum insulin levels were 46.4% higher (P=0.003). Glucose levels (mean [interquartile range]) were significantly lower on Day 3 for PP (168.2 [145.8] mg/dL vs. 139.4 [77.8] mg/dL; P=0.013), but not significantly so for CP (159.0 [66.1] mg/dL vs. 139.5 [57.9] mg/dL; P=0.084). Mean insulin levels were significantly higher on Day 3 for CP (195 [120] pmol/L vs. 230 [90] pmol/L; P=0.01), but not significantly so for PP (178 [106] pmol/L vs. 194 [120] pmol/L; P=0.099). There were no significant differences between the two catheter lengths. CONCLUSIONS: Postprandial glycemic excursions were lower on Day 3 of catheter wear time, but there were no differences between PPs and CPs. These findings support the proposal that catheter wear time plays an important role in insulin absorption.
Authors: Karena L Swan; James D Dziura; Garry M Steil; Gayane R Voskanyan; Kristin A Sikes; Amy T Steffen; Melody L Martin; William V Tamborlane; Stuart A Weinzimer Journal: Diabetes Care Date: 2008-11-18 Impact factor: 17.152
Authors: Stefan Lindpointner; Stefan Korsatko; Gerd Köhler; Hans Köhler; Roland Schaller; Ruthy Kaidar; Ofer Yodfat; Lukas Schaupp; Martin Ellmerer; Thomas R Pieber; Werner Regittnig Journal: Diabetes Care Date: 2009-12-29 Impact factor: 17.152
Authors: Christopher James Rini; Elaine McVey; Diane Sutter; Stephen Keith; Heinz-Joerg Kurth; Leszek Nosek; Christoph Kapitza; Kerstin Rebrin; Laurence Hirsch; Ronald J Pettis Journal: Drug Deliv Transl Res Date: 2015-08 Impact factor: 4.617
Authors: Paolo Pozzilli; Tadej Battelino; Thomas Danne; Roman Hovorka; Przemyslawa Jarosz-Chobot; Eric Renard Journal: Diabetes Metab Res Rev Date: 2015-06-22 Impact factor: 4.876
Authors: Mark Evans; Antonio Ceriello; Thomas Danne; Christophe De Block; J Hans DeVries; Marcus Lind; Chantal Mathieu; Kirsten Nørgaard; Eric Renard; Emma G Wilmot Journal: Diabetes Obes Metab Date: 2019-06-19 Impact factor: 6.577